−2.67USD
−132.49 MUSD
20.76 MUSD
57.71 M
About C4 Therapeutics, Inc.
Sector
Industry
CEO
Andrew J. Hirsch
Website
Headquarters
Watertown
Employees (FY)
145
Founded
2015
FIGI
BBG00BV2Y9B7
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CCCC is 6.61 USD — it has decreased by 4.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange C4 Therapeutics, Inc. stocks are traded under the ticker CCCC.
C4 Therapeutics, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
CCCC stock is 7.04% volatile and has beta coefficient of 5.79. Check out the list of the most volatile stocks — is C4 Therapeutics, Inc. there?
CCCC earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.66 USD resulting in a 17.08% surprise. The estimated earnings for the next quarter are −0.69 USD per share. See more details about C4 Therapeutics, Inc. earnings.
C4 Therapeutics, Inc. revenue for the last quarter amounts to 11.07 M USD despite the estimated figure of 5.28 M USD. In the next quarter revenue is expected to reach 3.20 M USD.
Yes, you can track C4 Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CCCC stock has fallen by 3.64% compared to the previous week, the month change is a 19.39% fall, over the last year C4 Therapeutics, Inc. has showed a 110.51% increase.
CCCC net income for the last quarter is −34.75 M USD, while the quarter before that showed −27.04 M USD of net income which accounts for −28.54% change. Track more C4 Therapeutics, Inc. financial stats to get the full picture.
Today C4 Therapeutics, Inc. has the market capitalization of 473.35 M, it has increased by 0.44% over the last week.
No, CCCC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CCCC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade C4 Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 145.00 employees. See our rating of the largest employees — is C4 Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So C4 Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating C4 Therapeutics, Inc. stock shows the neutral signal. See more of C4 Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on C4 Therapeutics, Inc. future price: according to them, CCCC price has a max estimate of 60.00 USD and a min estimate of 7.00 USD. Read a more detailed C4 Therapeutics, Inc. forecast: see what analysts think of C4 Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. C4 Therapeutics, Inc. EBITDA is −131.29 M USD, and current EBITDA margin is −632.56%. See more stats in C4 Therapeutics, Inc. financial statements.